FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising an expression inhibitor TSC22D4, a recombinant expression vector, a recombinant cell, a pharmaceutical composition, use of said inhibitor, vector, cell or composition for prevention, regulation and/or treatment of disease, selected from insulin resistance, hypertension, dyslipidemia, coronary artery disease, metabolic syndrome and/or type 1 or 2 diabetes mellitus and/or to improve insulin sensitivity and a therapeutic kit for preventing, regulating and/or treating the above diseases. In one version, the expression inhibitor TSC22D4 is an interfering ribonucleic acid, a protein nucleic acid or a closed nucleic acid and contains at least one of the following sequences: 5'-GGACGUGUGUGGAUGUUUAdTdT-3'; 5'-GGAUGUUUACGAGAGAGAUdTdT-3'; 5'-AGUCCCACCUCAUGUUUGCdTdT-3'.
EFFECT: invention extends the range of products for inhibiting expression of TSC22D4.
13 cl, 3 dwg, 6 ex
